Efficacy and Safety of Precision Therapy in Refractory Tumor

Refractory Tumor Clinical Trial

Official title: Efficacy and Safety of Precision Therapy in Refractory Tumor (Long March Pathway)

Status Recruiting

Clinical Trial Summary

This study is intended to evaluate efficacy and safety of targeted precision therapy in patients with refractory tumor, including rare tumor without standard recommended treatment and common tumor after multiple line of therapy.

Clinical Trial Description

The individuals recruited in the present study are with solid tumor, mainly including two parts: first, rare tumor without standard recommended treatment such as atypical fibrous histiocytoma; second, common tumor after multiple line of therapy such as lung cancer, gastric cancer, colorectal cancer, etc. All patients have no any standard therapy based on NCCN guideline when recruiting. Next-generation sequence was used to detect druggable molecular event including gene mutation, gene fusion, amplification, etc. Then patients with molecular events were treated with corresponding targeted drug and followed-up, and not limited tumor type. PD-1/L1 inhibior plus anti-angiogenic agent was used in patients without durgguable targets. The efficacy and safety of these regimens were evaluated. ;

Related Conditions & MeSH terms

• Neoplasms
• Rare Tumor
• Refractory Tumor

• NCT number: NCT03239015
• Study type: Interventional
• Source: Shanghai Changzheng Hospital
• Contact: Xiao-dong Jiao, MD.PHD
• Phone: +86-13817797639
• Email: pulava@163.com
• Status: Recruiting
• Phase: Phase 2
• Start date: January 1, 2017
• Completion date: December 31, 2023